LONDON (Reuters) - Treating COVID-19 patients at home with a commonly-used inhaled asthma drug called budesonide can speed up their recovery, according to UK trial results on Monday which doctors said ...

Young woman using asthma inhaler at home. The NDA submission is supported by data from the phase 3 MANDALA trial, which included 3132 patients with moderate to severe asthma. The Food and Drug ...

AS VACCINATION against covid-19 gathers speed, the end of the covid-19 pandemic is starting to hover on the horizon. But not everyone will take the vaccine and none of the jabs is 100% effective at ...

This randomised, double-blind, double-dummy crossover study was designed to compare the pharmacokinetic profile and pulmonary bioavailability of budesonide 1000µg delivered by inhalation as a powder ...

Please provide your email address to receive an email when new articles are posted on . The complete response letter (CRL) denied approval for budesonide oral suspension (BOS) and recommended ...

UCERIS is now available for patients through the public drug plans of five Canadian provinces: Ontario, Quebec, Saskatchewan, New Brunswick and Nova Scotia. These first public drug plan listings for ...

Please provide your email address to receive an email when new articles are posted on . Takeda Pharmaceutical Company Limited announced it received an FDA complete response letter in response to its ...

PHILADELPHIA Patients with stage 3 or 4 melanoma taking ipilimumab (a human monoclonal antibody being developed by Bristol-Myers Squibb and Medarex) and the oral steroid budesonide to reduce side ...

The FDA granted accelerated approval for the first drug to reduce proteinuria in primary immunoglobulin A (IgA) nephropathy, the agency announced on Wednesday. The delayed released budesonide (Tarpeyo ...

Treating COVID-19 patients at home with a commonly-used inhaled asthma drug called budesonide can speed up their recovery, according to UK trial results on Monday which doctors said could change the ...